Cargando…

Lowering HIV fitness and replication rate by administration of lamivudine alone, in extensively resistant HIV-infected patients, as a "bridging" strategy towards optimized salvage regimens

Detalles Bibliográficos
Autor principal:	Manfredi, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315920/ http://dx.doi.org/10.1186/1742-4690-7-S1-P58

Ejemplares similares

Lamivudine monotherapy as a holding regimen for HIV-positive children
por: Patten, Gabriela, et al.
Publicado: (2018)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Intrinsic Replication Competences of HIV Strains After Zidovudine/Lamivudine/Nevirapine Treatment in the Philippines
por: Kageyama, Seiji, et al.
Publicado: (2019)

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023)

More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort
por: Rokx, Casper, et al.
Publicado: (2014)

Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children
por: Bunupuradah, Torsak, et al.
Publicado: (2015)

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV
por: Rolle, Charlotte-Paige, et al.
Publicado: (2021)

Abacavir/lamivudine combination in the treatment of HIV: a review
por: Sivasubramanian, Geetha, et al.
Publicado: (2010)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
por: Zamora, Francis J, et al.
Publicado: (2019)

Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens
por: Priest, Julie, et al.
Publicado: (2023)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
por: Manosuthi, Weerawat, et al.
Publicado: (2010)

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China
por: Gu, Lijun, et al.
Publicado: (2015)

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis
por: Luo, Aoran, et al.
Publicado: (2018)

Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults
por: Ho, Sharlene, et al.
Publicado: (2020)

Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate
por: Greaves, Wayne, et al.
Publicado: (2019)

HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review
por: Patel, Rickesh, et al.
Publicado: (2021)

Lack of Effect of Lamivudine on Ebola Virus Replication
por: Hensley, Lisa E., et al.
Publicado: (2015)

Adefovir Dipivoxil Alone or in Combination with Ongoing Lamivudine in Patients with Decompensated Liver Disease and Lamivudine-resistant Hepatitis B Virus
por: Kim, Kang Mo, et al.
Publicado: (2005)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022)

Zidovudine/Lamivudine for HIV-1 Infection Contributes to Limb Fat Loss
por: van Vonderen, Marit G. A., et al.
Publicado: (2009)

Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients
por: Radford, Matthew, et al.
Publicado: (2019)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
por: Wang, Ruolan, et al.
Publicado: (2023)

Towards an ideal antiretroviral regimen for the global HIV epidemic
por: Grinsztejn, Beatriz, et al.
Publicado: (2017)

Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
por: Larru, Beatriz, et al.
Publicado: (2007)

Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen
por: Engsig, Frederik N, et al.
Publicado: (2010)

Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens
por: Fokam, Joseph, et al.
Publicado: (2023)

Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand
Publicado: (2016)

Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?
por: Giacomelli, Andrea, et al.
Publicado: (2020)

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
por: Suárez-García, Inés, et al.
Publicado: (2023)

Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults
por: Li, Jin, et al.
Publicado: (2022)

The NRTIs Lamivudine, Stavudine and Zidovudine Have Reduced HIV-1 Inhibitory Activity in Astrocytes
por: Gray, Lachlan R., et al.
Publicado: (2013)

Severe skin rash with lamivudine in HIV infected patients: Some unusual case reports
por: Modak, Dolanchampa, et al.
Publicado: (2013)

Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations
por: Cruciani, Mario, et al.
Publicado: (2015)

Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection
por: Quercia, Romina, et al.
Publicado: (2018)

A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1
por: Shin, Sang-Kyu, et al.
Publicado: (2023)

Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study
por: Lombardi, Francesca, et al.
Publicado: (2023)

The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy
por: Cai, Qingqing, et al.
Publicado: (2016)

Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis
por: Alzate Angel, Juan Carlos, et al.
Publicado: (2017)

Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mt0qvqumohv0oldgqrnth6i1dl